A Combination of Broadly Neutralizing HIV-1 Monoclonal Antibodies Targeting Distinct Epitopes Effectively Neutralizes Variants Found in Early Infection

Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Journal of Virology (Impact Factor: 4.44). 07/2012; 86(19):10857-61. DOI: 10.1128/JVI.01414-12
Source: PubMed


Neutralizing antibody protection against HIV-1 may require broad and potent antibodies targeting multiple epitopes. We tested 7 monoclonal antibodies (MAbs) against 45 viruses of diverse subtypes from early infection. The CD4 binding site MAb NIH45-46W was most broad and potent (91% coverage; geometric mean 50% inhibitory concentration [IC(50)], 0.09 μg/ml). Combining NIH45-46W and a V3-specific MAb, PGT128, neutralized 96% of viruses, while PGT121, another V3-specific MAb, neutralized the remainder. Thus, 2 or 3 antibody specificities may prevent infection by most HIV-1 variants.

Download full-text


Available from: Leslie Goo, Jan 20, 2016
  • [Show abstract] [Hide abstract]
    ABSTRACT: To protect against HIV infection, passively transferred and/or vaccine-elicited neutralizing antibodies (NAbs) need to effectively target diverse subtypes that are transmitted globally. These variants are a limited subset of those present during chronic infection and display some unique features. In the case of mother-to-child transmission (MTCT), transmitted variants tend to be resistant to neutralization by maternal autologous NAbs. To investigate whether variants transmitted during MTCT are generally resistant to HIV-1-specific NAbs, 107 maternal or infant variants representing the dominant HIV-1 subtypes were tested against six recently identified HIV-1-specific broadly neutralizing monoclonal antibodies (bNAbs), NIH45-46W, VRC01, PGT128, PGT121, PG9 and PGT145. Infant and maternal variants did not differ in their neutralization sensitivity to individual bNAbs, nor did viruses from transmitting versus nontransmitting mothers, although there was a trend for viruses from transmitting mothers to be less sensitive overall. No single bNAb neutralized all viruses, but a combination of bNAbs that target distinct epitopes covered 100% of the variants tested. Compared with heterosexually transmitted variants, vertically transmitted variants were significantly more sensitive to neutralization by PGT128 and PGT121 (P = 0.03 in both cases), but there were no differences for the other bNAbs. Overall, subtype A variants were significantly more sensitive to NIH45-46 (P = 0.04), VRC01 (P = 0.002) and PGT145 (P = 0.03) compared with the nonsubtype A and less sensitive to PGT121 than subtype Cs (P = 0.0001). A combination of bNAbs against distinct epitopes may be needed to provide maximum coverage against viruses in different modes of transmission and diverse subtypes.
    No preview · Article · Jun 2013 · AIDS (London, England)
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We compared the neutralization sensitivity of early/transmitted HIV-1 variants from patients infected by subtype B viruses at 3 periods of the epidemic (1987-1991, 1996-2000, 2006-2010). Infectious pseudotyped viruses expressing envelope glycoproteins representative of the viral quasi-species infecting each patient were tested for sensitivity to neutralization by pools of sera from HIV-1 chronically infected patients and by an updated panel of 13 human monoclonal neutralizing antibodies (HuMoNAbs). A progressive significantly enhanced resistance to neutralization was observed over calendar time, by both human sera and most of the HuMoNAbs tested (b12, VRC01, VRC03, NIH45-46(G54W), PG9, PG16, PGT121, PGT128, PGT145). Despite this evolution, a combination of two HuMoNAbs (NIH45-46(G54W) and PGT128) still would efficiently neutralize the most contemporary transmitted variants. In addition, we observed a significant reduction of the heterologous neutralizing activity of sera from individuals infected most recently (2003-2007) compared to patients infected earlier (1987-1991), suggesting that the increasing resistance of the HIV species to neutralization over time coincided with a decreased immunogenicity. These data provide evidence for an ongoing adaptation of the HIV-1 species to the humoral immunity of the human population, which may add an additional obstacle to the design of an efficient HIV-1 vaccine.
    Full-text · Article · Jul 2013 · PLoS Pathogens
  • [Show abstract] [Hide abstract]
    ABSTRACT: The HIV-1 envelope (Env) glycoprotein gp120 is heavily glycosylated, displaying an array of high mannose and complex carbohydrate moieties that are tightly packed and arranged into spatially distinct clusters. It is well established that together these glycans form an evolving shield that protects vulnerable receptor-binding sites from recognition by neutralizing antibodies. Paradoxically, the absence of glycans has been consistently associated with HIV-1 transmission in certain settings, but the underlying benefit for transmission remains poorly understood. A less glycosylated form of the viral Env may be more sensitive to neutralizing antibodies (nAbs) in an established infection; yet in the absence of adaptive immunity, this could be advantageous by providing evasion from mucosal immune defenses directed against pathogen-associated glycans or an enhanced ability to attach to and infect its primary target, the CCR5+ CD4+ T cell. Thus, HIV-1 must continually maintain a delicate balance between the number, position, and type of glycans in Env in response to host-selective pressures. Here we will explore the complex roles that glycans play in establishing new infections, maintaining Env function, and evading sequential waves of neutralizing antibodies. © Springer Science+Business Media New York 2014. All rights are reserved.
    No preview · Chapter · Jan 2014
Show more